Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health & Wellness Today New York.
Press releases published on July 16, 2025
Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement
GlobeNewswire
·
July 16, 2025
CINCINNATI, July 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) and Ocuvex Therapeutics, Inc. (“Ocuvex”), a privately held biopharmaceutical company focused on the development and commercialization of ophthalmic …
Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements
GlobeNewswire
·
July 16, 2025
Commack, NY, July 16, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers …
Full Alliance Group Launches Development of YAHBEE SHOPPING NETWORK — A Web3-Driven, Peer-to-Peer Commerce Revolution
GlobeNewswire
·
July 16, 2025
TAMPA, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Full Alliance Group, Inc. (OTC: FAGI) (“the Company”), through its majority-owned subsidiary Qubitera Holdings, proudly announces the launch of the YAHBEE SHOPPING NETWORK — a groundbreaking platform that …
LIXTE Biotechnology Holdings Regains Compliance with Nasdaq’s Continued Listing Requirements
GlobeNewswire
·
July 16, 2025
PASADENA, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it has received a letter from the Nasdaq Hearings Panel …
Chiesi and Plug and Play Call for Innovative Solutions to Revolutionize Respiratory Care in the U.S.
GlobeNewswire
·
July 16, 2025
CARY, N.C., July 16, 2025 (GLOBE NEWSWIRE) -- Chiesi, an international biopharmaceutical company (Chiesi Group) and Plug and Play, the world’s largest Open Innovation platform, announced today the launch of Breathing Innovation: The Chiesi Challenge for …
MIMEDX to Host Second Quarter 2025 Operating and Financial Results Conference Call on July 30
GlobeNewswire
·
July 16, 2025
MARIETTA, Ga., July 16, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30, 2025 after the market close on …
ViaDerma Announces Posting of Annual Report and Ongoing Evaluation of Public Status in Response to Market Changes
GlobeNewswire
·
July 16, 2025
LOS ANGELES, July 16, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Expert Market: VDRM), a specialty pharmaceutical company, announced today that its 2024 Annual Report has been posted to the company’s official website, www.viaderma.com. Due to the company …
As the Americans with Disabilities Act turns 35, Joni Eareckson Tada’s advocacy continues
GlobeNewswire
·
July 16, 2025
Agoura Hills, CA, July 16, 2025 (GLOBE NEWSWIRE) -- For 35 years, the Americans with Disabilities Act has ensured legal safeguards that protect people with disabilities from discrimination in employment, education, transportation and other aspects of …
Proscia Cements Leadership in Diagnostic Pathology with 400% Growth in Daily Cases
GlobeNewswire
·
July 16, 2025
Amid momentum, the company generates millions in new high-margin revenue for diagnostic network Introduces AI application suites to demonstrate the future of pathology for high-impact use cases Launches 24/7 support to meet the demands of mission-critical, …
Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)
GlobeNewswire
·
July 16, 2025
• Provides Protection Through Sept. 2044; Will Be Listed in FDA’s Orange Book CONSHOHOCKEN, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for …
Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer
GlobeNewswire
·
July 16, 2025
Additional complete response (CR) observed in patient with multiple tumors Confirmed overall response rate (ORR) of 50% in patients with combined positive score (CPS) ≥1, including 50% ORR in patients with low CPS (1-19) 12-month overall survival of 88% …
Vantive and Innovative Renal Care Enter into a Long-Term Agreement Focused on Enhanced Use of Technology to Expand Home Dialysis Therapies
GlobeNewswire
·
July 16, 2025
DEERFIELD, Ill. and FRANKLIN, Tenn., July 16, 2025 (GLOBE NEWSWIRE) -- Vantive, a vital organ therapy company with a 70-year legacy of kidney care innovation, and Innovative Renal Care (IRC), a comprehensive kidney care provider for patients across the U.S …
Qualigen Granted New Patents Covering 25 Countries
GlobeNewswire
·
July 16, 2025
CARLSBAD, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company” or “Qualigen”) is announcing an update on patents granted in the first six months of 2025. The patent is Titled “Substitued Naphthalene Diimides …
Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC
GlobeNewswire
·
July 16, 2025
- Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI 12), 52% on activities of daily living, 91% on cognitive fluctuations, and 62% on motor symptoms as compared to placebo - - Additional presentations highlight positive …
Jaya Biosciences Receives Patent Notices of Allowance in Japan, China, and Singapore for Novel Methods of Treating Neurological Diseases, including Alzheimer’s, Further Strengthening its Global Intellectual Property Portfolio
GlobeNewswire
·
July 16, 2025
SOUTH SAN FRANCISCO, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Jaya Biosciences, Inc. (“JayaBio” or “the Company”), a privately held early-stage life-sciences company developing CNS-directed gene therapies for unmet needs in the neurodegenerative diseases, …
Venus Concept to Release Second Quarter of Fiscal Year 2025 Financial Results on August 14, 2025
GlobeNewswire
·
July 16, 2025
TORONTO, July 16, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that second quarter of fiscal year 2025 financial results will be released after …
CVRx Announces Positive News on Outpatient Payment for Barostim
GlobeNewswire
·
July 16, 2025
MINNEAPOLIS, July 16, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) has proposed to keep the Barostim implant procedure as …
Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism
GlobeNewswire
·
July 16, 2025
CELEBRATION, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced the publication of “Long-term …
Fortrea Announces Date for Second Quarter 2025 Financial Results and Conference Call
GlobeNewswire
·
July 16, 2025
DURHAM, N.C., July 16, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its second quarter 2025 financial results before the market opens on …
Amphista Therapeutics announces achievement of a research milestone in its collaboration with Merck triggering a milestone payment
GlobeNewswire
·
July 16, 2025
Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue™ degraders for oncology and immunology indications Cambridge, UK, 16 July 2025 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery of next-generation, …